Stock Events

Stock Events

Scynexis 

$4.17
55
-$0.07-1.54% Today

Statistics

Day High
4.37
Day Low
4.18
52W High
9.44
52W Low
4.15
Volume
572,696
Avg. Volume
-
Mkt Cap
174.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-3.36
-2.25
-1.13
-0.02
Expected EPS
-0.506667
Actual EPS
N/A

Financials

-568.29%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
7.49MRevenue
-42.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCYX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.38B
Pfizer is a global pharmaceutical company that competes with Scynexis in the development of antifungal and antibacterial drugs.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. is involved in the development of anti-infective drugs, directly competing with Scynexis' focus on antifungal treatments.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc. offers antifungal and antiviral therapies, making it a competitor in the infectious disease market.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca PLC has a portfolio that includes anti-infective drugs, competing with Scynexis in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that compete with Scynexis' drug offerings.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie Inc. competes in the antifungal space with its own range of products, posing competition to Scynexis.
Novartis
NVS
Mkt Cap292.07B
Novartis AG engages in the development of drugs to treat a wide range of infections, including fungal, competing with Scynexis.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. has a diverse biopharmaceutical portfolio that includes treatments for infections, competing with Scynexis.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb has a range of anti-infective drugs, making it a competitor in the same market as Scynexis.
Sanofi
SNY
Mkt Cap105.92B
Sanofi operates in the pharmaceutical sector with a focus on anti-infectives among other areas, competing with Scynexis.

About

SCYNEXIS, Inc. is a biotechnology firm based in the U.S. dedicated to developing therapies for fungal infections. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), has received approval for the treatment of vulvovaginal candidiasis (VVC). Furthermore, SCYNEXIS is progressing ibrexafungerp, its leading drug candidate, as both an oral and intravenous medicine designed to address various fungal conditions, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and challenging refractory invasive fungal infections. Ibrexafungerp has successfully completed the Phase 3 CANDLE study, which evaluated its effectiveness in preventing recurrent VVC. SCYNEXIS has also established collaborative research and commercialization agreements for ibrexafungerp with partners such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. Founded in 1999, the company is headquartered in Jersey City, New Jersey, and changed its name from SCYNEXIS Chemistry & Automation, Inc. to its current designation in June 2002.
Show more...
CEO
Dr. David Gonzalez Angulo M.D.
Employees
28
Country
United States
ISIN
US8112923094

Listings

F
DE
135.F
XNAS
US
SCYX
LSE
GB
0L49.LSE
MU
DE
135.MU

0 Comments

Share your thoughts

FAQ

What is Scynexis stock price today?▼
The current price of SCYX is $4.17 USD — it has decreased by -1.54% in the past 24 hours. Watch Scynexis stock price performance more closely on the chart.
What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scynexis stocks are traded under the ticker SCYX.
Is Scynexis stock price growing?▼
SCYX stock has fallen by -6.4% compared to the previous week, the month change is a -29.65% fall, over the last year Scynexis has showed a -35.53% decrease.
What is Scynexis market cap?▼
Today Scynexis has the market capitalization of 174.78M
When is the next Scynexis earnings date?▼
Scynexis is going to release the next earnings report on August 17, 2026.
What were Scynexis earnings last quarter?▼
SCYX earnings for the last quarter are -3.36 USD per share, whereas the estimation was -0.99 USD resulting in a -240.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scynexis revenue for the last year?▼
Scynexis revenue for the last year amounts to 7.49M USD.
What is Scynexis net income for the last year?▼
SCYX net income for the last year is -42.58M USD.
How many employees does Scynexis have?▼
As of June 15, 2026, the company has 28 employees.
In which sector is Scynexis located?▼
Scynexis operates in the Health & Wellness sector.
When did Scynexis complete a stock split?▼
The last stock split for Scynexis was on June 01, 2026 with a ratio of 1:8.
Where is Scynexis headquartered?▼
Scynexis is headquartered in Jersey City, United States.